Somewhat Positive Press Coverage Somewhat Unlikely to Impact Neogen (NEOG) Stock Price

News headlines about Neogen (NASDAQ:NEOG) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neogen earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.4832979225537 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

NEOG stock opened at $69.89 on Friday. The firm has a market capitalization of $3,585.02, a price-to-earnings ratio of 81.27, a P/E/G ratio of 4.11 and a beta of 1.27. Neogen has a 1 year low of $45.01 and a 1 year high of $70.41.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings results on Thursday, March 22nd. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. The company had revenue of $95.90 million for the quarter, compared to analyst estimates of $97.93 million. Neogen had a return on equity of 11.49% and a net margin of 14.82%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company earned $0.27 earnings per share. equities research analysts anticipate that Neogen will post 1.13 EPS for the current fiscal year.

A number of equities research analysts have issued reports on NEOG shares. Roth Capital set a $62.00 target price on Neogen and gave the company a “hold” rating in a research note on Thursday, January 4th. Zacks Investment Research upgraded Neogen from a “hold” rating to a “strong-buy” rating and set a $69.00 target price on the stock in a research note on Saturday, January 6th. Stephens reiterated a “hold” rating and issued a $62.00 target price on shares of Neogen in a research note on Wednesday, January 10th. BidaskClub cut Neogen from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Finally, ValuEngine upgraded Neogen from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Neogen currently has a consensus rating of “Hold” and a consensus price target of $65.25.

In other news, Director G Bruce Papesh sold 6,000 shares of the firm’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $59.72, for a total transaction of $358,320.00. Following the transaction, the director now directly owns 18,196 shares of the company’s stock, valued at $1,086,665.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James L. Herbert sold 20,000 shares of the firm’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $68.50, for a total value of $1,370,000.00. Following the transaction, the insider now directly owns 1,150,926 shares in the company, valued at $78,838,431. The disclosure for this sale can be found here. Insiders have sold 113,202 shares of company stock worth $7,087,826 over the last three months. Corporate insiders own 4.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at

About Neogen

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.

Insider Buying and Selling by Quarter for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with's FREE daily email newsletter.

Leave a Reply